Replies to post #242459 on Avid Bioservices Inc (CDMO)

[swg_tdr]

cjgaddy, much appreciated

in fact, this listing is mind-boggling, needs a sticky

best,

[pphmtoolong]

cjgaddy, I am very confident that Peregrine will not disappoint those of us crazy enough to walk this road with them. When the big news from Sunrise or a big money partnership is announced, we will see a multi-dollar move IMO. Too bad these penny moves frequently dissipate.

GLTA, Especially Bavi-arm Sunrise Patients,

Paul

[biopharm]

CJ, very nice! I'm not sure if "Ambit.." would be considered, since we have no 100% PR on that and we only have a Peregrine Pharmaceuticals employee with a linkedin profile = Tom Sklenar that also shows employed by Ambit...

------------

Current
Ambit Biosciences,
Peregrine Pharmaceuticals


Sr. Clinical Trial Manager
Ambit Biosciences: January 2014 – Present (2 months)

Sr. Clinical Trial Manager
Peregrine Pharmaceuticals August 2011 – Present (2 years 7 months)

And for those that like to make BMY connections:

Mark Foletta, (ex Amylin before BMY deal in 2012) was appointed to the board of Ambit Biosciences in the same month (JAN 2014) that Tom Sklenar started his double employment (PPHM+Ambit)

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114368100

------------------

To be honest, IF IF Ambit is close to BMS and it seems like Peregrine tries to stay far clear away from BMS/Opdivo now... maybe Ambit does not mean much at all

It still makes me think back of the Medarex <> PPHM collaboration back in 2005 and what if Medarex used CSM in Fargo ND back during those early years and is it out of the realm of possibility that BMS sort of knew the value of Opdivo+Bavituximab way back then.

I'm not sure... but just strange how BMS buys out Medarex and moves forward with Opdivo and with all the sabotage rooted back to CSM in Fargo ND, maybe BMS had plans all along to try and dominate market share with Opdivo+Bavituximab all by themselves, but know Bavituximab is in the hands of dozens of collaborators and possibly completely backfired on BMS

------------------

Nivolumab (nye vol' ue mab; ONO-4538, BMS-936558, or MDX1106), marketed as Opdivo, is a human IgG4 anti-PD-1 monoclonal antibody developed by Ono Pharmaceutical and Medarex (later acquired by Bristol-Myers Squibb) for the treatment of cancer.[1][2] Nivolumab acts as an immunomodulator by blocking ligand activation of the programmed cell death 1 (PD-1) receptor on activated T cells.

https://en.wikipedia.org/wiki/Nivolumab

http://ignition.co/327

---------------

2005 Peregrine and Medarex

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=266115

[biopharm]

Great post CJ with collaborators of Peregrine, now CDMO and wonder how many have continued ...

As for Dr Bernard Fox and his once ambition to use OX40, I wonder how convincing Dr Wolchok was in showing the better safety profile one can have with PS Targeting and I am sure more Biomarker discoveries would have been determined by comparison. Anyhow I am sure safety is #1 now ...knowing the FDA can use Biomarker data to prove that adverse events / patient deaths could be caused from OX40...or other off target toxicity causing drugs, where just a few years ago it would not raise a flag but Biomarkers are changing all that now.

"Other work by UbiVac and the firm’s collaborators has shown that a single dose of UbiVac’s DRibble cancer vaccine and anti-OX40 can significantly increase survival and provide apparent cure in about one third of animals bearing an advanced, difficult to treat, breast cancer. (NATURE Scientific Reports 22 November 2016) This and other research has motivated UbiVac to initiate a clinical trial combining both agents."

https://www.oregonbio.org/2017/10/13/portland-based-immuno-oncologist-dr-bernard-a-fox-to-present-at-siena-italy-conference/
http://www.ubivac.com

____

FROM PPHM’s 4-3-17 PR: http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=1019762

…”Latest Findings from Ongoing Collaboration with Memorial Sloan Kettering (MSK) Support Potential Applications for Combining CAR T & Anti-PS in Treatment of Solid Tumors”… For this study, a team of MSK researchers led by cancer immunotherapy thought-leaders, Taha Merghoub, Ph.D. and Jedd D. Wolchok, M.D., Ph.D., evaluated and compared the anti-tumor activity and off-target toxicities of adoptive T cell transfer therapy in combination with either PS-targeting antibodies or anti-OX40 antibodies in mice with advanced melanomas. Whereas PS-targeting and anti-OX40 demonstrated comparable tumor regression when administered in combination with transferred adoptive T cells, only the PS-targeting combination achieved these results without any off-target toxicities. By contrast, the anti-OX40 treatment combination triggered off-target inflammatory destruction of healthy tissues. Additional study results demonstrated that the PS-targeting antibodies decreased tumor-induced immunosuppression as evidenced by a decrease in immunosuppressive regulatory T cells (Tregs) and M2 macrophages. This finding is consistent with Peregrine’s belief that bavituximab may modulate the immunosuppressive tumor microenvironment and enhance the activity of immunotherapy agents.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=130490016